Cibinetide de Araim Improves Endothelial-Cell-Mediated Vascular Regeneration for the Treatment of Re


TARRYTOWN, N.Y., April 1, 2019 / PRNewswire / – Cibinetide, the main compound of Araim Pharmaceuticals, Inc., Recently, a clinical stage biotechnology company pioneering the development of the innate repair receptor activating platform (IRR) technology has been shown to improve the efficacy of endothelial colony-forming cell transplantation (ECFC) to repair retinal vasculature . ECFC is a type of stem cell capable of healing and rebuilding damaged blood vessels in the retina.

Research presented in a recently published paper, O & # 39; Leary et al. Exp Eye Res 2019, sought to assess ECFC as a therapeutic cellular treatment in a mouse model of retinal ischemia, and the ability of cibinetide to increase the efficacy of this treatment. Cibinetide uses the immune-mediated innate body repair system to activate tissue repair due to stress or injury. In vitro, the cytokine was able to improve the survival of ECFCs exposed to oxidative stress. In addition, the systemic treatment of mice with cytokines led to a decrease in inflammatory mediators, such as IL-1β and TNF-α in the ischemic retina and cerebral microglia, and homing of ECFCs injected into damaged vessels was significantly increased, repairing vessels and revascularizing the retina. Alan StittUniversity of the Queen, Belfast, United Kingdom"We found that the ability to significantly suppress stressors in the retinal environment allows the transplanted cells to survive and harbor the targets for repair." Cibinetide significantly increases the clinical value of this cellular therapy and has a clear potential for advancement the approach in a viable treatment option for this blinding disease. "

Cibinetide works via binding to the TIR, which is expressed in response to stress, such as ischemia. Ischemia leads to a cascade of inflammatory signals, including cytokine release and cell death. The binding of the cytokine to the IRR leads to the activation of multiple intracellular signaling pathways that decrease inflammation while simultaneously activating cell and tissue repair. Similar effects were observed in the preservation and repair of burned skin vessels (Bohr et al., PNAS 2013), and the cytokine's ability to improve islet cell transplantation in diabetic mice (Watanabe et al., Transplantation 2015) .

The retina contains the light-sensitive neurons in the back of the eye. It has one of the highest rates of oxygen consumption of any tissue in the body. Ischemia, decreased or absent blood supply providing oxygen and nutrients, may result from vessel blockage to the retina or vascular problems related to diabetes. Progressive retinal ischemia causes positive regulation of inflammatory mediators within the eye, leading to abnormal growth of the retinal blood vessels and / or leak, both of which cause vision loss and blindness if left untreated. Available treatments include surgery, steroid treatment or anti-VEGF eye injections, or laser photocoagulation. Such treatments may be effective but generally have side effects and do not address the underlying cause of the disease. This emerging treatment modality for delivering therapeutic stem cells directly into the eye is currently being evaluated with the hypothesis that they would provide neuroprotection and vascular regeneration, thus preventing progression to vision loss. The addition of cytokine enhances this effect.

About retinal ischemia

Retinal ischemia, defined as decreased blood flow to the retina, underlies the pathology of several important retinal diseases, including diabetic retinopathy, retinopathy of prematurity, and retinal vascular occlusive disease. Ischemia causes overproduction of VEGF, leading to increased vessel permeability and neovascularization. Current treatments are injections of anti-VEGF into the eye, laser repair and vitrectomy, which are effective, but do not address the underlying ischemia in the retina.

About Araim Pharmaceuticals, Inc.

Araim Pharmaceuticals, Inc. is a privately owned biopharmaceutical company with a library of peptides that activate the body's own immune system to repair chronic disease damage and slow down the aging process. We are focused on offering new therapies that slow, stop and reverse chronic conditions. Through an extensive preclinical program, the Araim IRR agonist library demonstrated in a wide range of disease conditions to activate the endogenous system to reduce inflammation, stop the spread of the lesion, and activate healing and regeneration. Our most advanced program, the Cyclot, completed Phase 2 trials in Diabetic Neuropathy and Sarcoid Neuropathy with demonstrated nerve regeneration.

See the original content for downloading multimedia: 300821512 .html

SOURCE Araim Pharmaceuticals, Inc.


Source link